Amitriptyline

5 trials NNeurology/Psychiatry

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

0 Recruiting

5 Completed trials

3 Sponsors

3 Countries

Phase III

Phase II

Phase III: 4 Phase II: 1

Oversight events:

8 temporary halts 4 corrective measures across 4 trials

View oversight register →

Sponsors using this IMP

Apurano Pharmaceuticals GmbH 4 Cannaxan GmbH 4 Oncopole Claudius Regaud 1

All trials

5 total

Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy Ended

2022-500897-32-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
Efficacy and Tolerability of AP707 in Patients with chronic Pain due to traumatic or post-operative peripheral Neuropathy Ended

2022-500898-13-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
Efficacy and Tolerability of AP707 in Patients with chronic pain due to central Neuropathy of any Genesis Ended

2022-500899-66-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
Efficacy and Tolerability of AP707 in Patients with Chronic Back Pain Ended

2022-502151-54-00 Phase III 2 countries Apurano Pharmaceuticals GmbH; Cannaxan GmbH
Phase II Randomized Controlled Study Aiming to Evaluate the Interest of Qutenza in Patients With ORL Cancer in Remission and With Sequellae … Ended

2024-515510-41-00 Phase II 1 country Oncopole Claudius Regaud

Showing 1–5 of 5 trials

← All drugs A–Z